ID   HCC-1.1
AC   CVCL_0C52
SY   HCC.1.1; HCC1.1; 3SP; 3sp
DR   Cosmic; 1628381
DR   Cosmic; 2162522
DR   Wikidata; Q54881504
RX   PubMed=18594539;
RX   PubMed=21364009;
RX   PubMed=23887712;
WW   https://lccl.zucmanlab.com/hcc/cellLines/HCC.1.1
DI   NCIt; C3098; Hepatitis C infection
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0C42 ! BLC-1
OI   CVCL_0C53 ! HCC-1.2
OI   CVCL_0C47 ! MF-1 [Human]
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 21-03-23; Version: 7
//
RX   PubMed=18594539; DOI=10.1038/sj.bjc.6604440;
RA   Sagmeister S., Eisenbauer M., Pirker C., Mohr T., Holzmann K.,
RA   Zwickl H., Bichler C., Kandioler D., Wrba F., Mikulits W., Gerner C.,
RA   Shehata M., Majdic O., Streubel B., Berger W., Micksche M.,
RA   Zatloukal K., Schulte-Hermann R., Grasl-Kraupp B.;
RT   "New cellular tools reveal complex epithelial-mesenchymal interactions
RT   in hepatocarcinogenesis.";
RL   Br. J. Cancer 99:151-159(2008).
//
RX   PubMed=21364009; DOI=10.1158/1535-7163.MCT-10-0917;
RA   van Zijl F., Mall S., Machat G., Pirker C., Zeillinger R.,
RA   Weinhaeusel A., Bilban M., Berger W., Mikulits W.;
RT   "A human model of epithelial to mesenchymal transition to monitor drug
RT   efficacy in hepatocellular carcinoma progression.";
RL   Mol. Cancer Ther. 10:850-860(2011).
//
RX   PubMed=23887712; DOI=10.1038/ncomms3218;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218.1-2218.7(2013).
//